Clinical trials: Liver Cancer (Primary and Metastatic)
Colorectal Cancer, Metastatic Cancer
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Metastatic Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005944
- Testing
- chemotherapy, fluorouracil, leucovorin calcium
- Where
- 18 sites in Belgium, France
- Sponsor
- UNICANCER
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion).
- Trial name
- NCT04544098
- Testing
- 177Lu-DOTATATE
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Cancer
Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00006010
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 17 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma, Liver Neoplasms
A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver
The purpose of this study is to determine the maximum tolerated dose (MTD) of ThermoDox when used in combination with radiofrequency ablation (RFA) in the treatment of primary and metastatic tumors of the liver.
- Trial name
- NCT00441376
- Testing
- ThermoDox
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Imunon
Liver Cancer, Metastatic Cancer
Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot…
- Trial name
- NCT00532740
- Testing
- Yttrium Y 90 glass microspheres
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Northwestern University
Liver Cancer, Liver Metastasis Colon Cancer
Clinical Validation of a Fractional Administration Device for Holmium-166 SIRT
To investigate the in vivo performance and safety of a novel medical device for the injection of holmium-166 microspheres during radioembolization.
- Conditions
- Liver Cancer, Liver Metastasis Colon Cancer, Primary Liver Cancer
- Trial name
- CONTROL (NCT05183776)
- Testing
- Fractional administration device
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Radboud University Medical Center
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases
Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases
This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in…
- Trial name
- YRENE (NCT07406126)
- Testing
- Yttrium-90 Radioembolization with standard systemic therapy
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fernando Gómez Muñoz
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Side-effect of Antibiotic
Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.
The aim of the study is to provide data on the pharmacokinetics (PK) of moxifloxacin (MXF) in serum and liver tissue of patients undergoing liver resection due to primary or secondary tumor of the liver.
- Trial name
- MOXI (NCT01302951)
- Testing
- Moxifloxacin 400 mg
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- University Hospital, Saarland
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Cancer, Metastatic Cancer
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have…
- Trial name
- NCT00003714
- Testing
- Pyrazoloacridine
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Metastatic Cancer
GEN2 Directed Cancer Immunotherapy Trial
Phase 1, non-randomized, open label dose escalation clinical trial evaluating the safety of GEN2 in participants with primary \& metastatic liver tumors.
- Trial name
- GEN2 (NCT04313868)
- Testing
- GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
- Where
- 4 sites in Philippines
- Volunteers
- 61 people
- Sponsor
- GenVivo, Inc.
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer.
- Trial name
- TACE (NCT03895359)
- Testing
- Stereotactic Body Radiation, Transarterial Chemoembolization
- Where
- Canada
- Volunteers
- 128 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Liver Cancer (Primary and Metastatic)
Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment
This study is a prospective, observational, real-world cohort study. We aim to establish a prospective database in the Department of Hepatobiliary and Pancreatic Surgery, systematically collecting and integrating patients'…
- Trial name
- NCT07587216
- Testing
- liver resection, Systemic therapy combined with locoregional interventions
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Tongji Hospital
Intrahepatic Cholangiocarcinoma, Liver Tumor
Treat Primary and Metastatic Liver Tumors
The use of Radiospheres in the management of intrahepatic cholangiocarcinoma is largely unknown and not reported in the medical literature.
- Conditions
- Intrahepatic Cholangiocarcinoma, Liver Tumor, Metastatic Cancer, Metastatic Liver Cancer
- Trial name
- NCT05240040
- Sponsor
- Methodist Health System
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute